Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abelacimab versus apixaban in cancer-associated venous thromboembolism
2021-003076-14Phase 3Active
- Sponsor
- Anthos Therapeutics
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abelacimab in venous thromboembolism (VTE) (2 arms), sponsored by Anthos Therapeutics. Primary endpoint: Time to first event of centrally adjudicated VTE recurrence through 6 months. Started Feb 2022; status: active.
02
Drugs
abelacimab
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2021-003076-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003076-14.